AU2003299561A1 - Compositions and methods for treating bacterial infections with protein-dalbavancin complexes - Google Patents

Compositions and methods for treating bacterial infections with protein-dalbavancin complexes

Info

Publication number
AU2003299561A1
AU2003299561A1 AU2003299561A AU2003299561A AU2003299561A1 AU 2003299561 A1 AU2003299561 A1 AU 2003299561A1 AU 2003299561 A AU2003299561 A AU 2003299561A AU 2003299561 A AU2003299561 A AU 2003299561A AU 2003299561 A1 AU2003299561 A1 AU 2003299561A1
Authority
AU
Australia
Prior art keywords
protein
compositions
methods
bacterial infections
treating bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299561A
Other languages
English (en)
Inventor
Marco Cavaleri
Luigi Colombo
Timothy Henkel
Daniela Jabes
Adriano Malabarba
Giorgio Mosconi
Martin Stogniew
Richard J. White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicuron Pharmaceuticals LLC
Original Assignee
Vicuron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32330046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003299561(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vicuron Pharmaceuticals LLC filed Critical Vicuron Pharmaceuticals LLC
Publication of AU2003299561A1 publication Critical patent/AU2003299561A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2003299561A 2002-11-18 2003-11-14 Compositions and methods for treating bacterial infections with protein-dalbavancin complexes Abandoned AU2003299561A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US42765402P 2002-11-18 2002-11-18
US60/427,654 2002-11-18
US48569403P 2003-07-08 2003-07-08
US60/485,694 2003-07-08
US49504803P 2003-08-13 2003-08-13
US60/495,048 2003-08-13
US49648303P 2003-08-19 2003-08-19
US60/496,483 2003-08-19
PCT/US2003/036399 WO2004046196A2 (en) 2002-11-18 2003-11-14 Compositions and methods for treating bacterial infections with protein-dalbavancin complexes

Publications (1)

Publication Number Publication Date
AU2003299561A1 true AU2003299561A1 (en) 2004-06-15

Family

ID=32330046

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2003299561A Abandoned AU2003299561A1 (en) 2002-11-18 2003-11-14 Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
AU2003294262A Expired AU2003294262B2 (en) 2002-11-18 2003-11-14 Methods of administering dalbavancin for treatment of bacterial infections
AU2003298662A Abandoned AU2003298662A1 (en) 2002-11-18 2003-11-14 Dalbavancin compositions for treatment of bacterial infections

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2003294262A Expired AU2003294262B2 (en) 2002-11-18 2003-11-14 Methods of administering dalbavancin for treatment of bacterial infections
AU2003298662A Abandoned AU2003298662A1 (en) 2002-11-18 2003-11-14 Dalbavancin compositions for treatment of bacterial infections

Country Status (14)

Country Link
US (12) US20050130909A1 (https=)
EP (1) EP1565201B1 (https=)
JP (3) JP5519090B2 (https=)
KR (2) KR101173310B1 (https=)
AU (3) AU2003299561A1 (https=)
CA (1) CA2506236C (https=)
DK (1) DK1565201T3 (https=)
ES (1) ES2712656T3 (https=)
HU (1) HUE041133T2 (https=)
IL (3) IL168327A (https=)
MX (1) MXPA05005338A (https=)
NO (1) NO20052362L (https=)
PT (1) PT1565201T (https=)
WO (3) WO2004045637A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
AU2003299561A1 (en) * 2002-11-18 2004-06-15 Vicuron Pharmaceuticals Inc. Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20090062182A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched dalbavancin
US8389583B2 (en) * 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
US20110132607A1 (en) * 2009-12-07 2011-06-09 Schlumberger Technology Corporation Apparatus and Technique to Communicate With a Tubing-Conveyed Perforating Gun
CA2904387C (en) 2013-03-15 2021-12-07 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
JP6540705B2 (ja) 2013-12-19 2019-07-10 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 生物学的液体処理システムのための遠隔操作弁
EP4509178A3 (en) 2014-07-17 2025-06-25 Melinta Therapeutics, LLC High purity oritavancin and method of producing same
HUE053347T2 (hu) 2014-11-06 2021-06-28 Xellia Pharmaceuticals Aps Glikopeptid-készítmények
WO2016140981A1 (en) * 2015-03-02 2016-09-09 Colonaryconcepts Llc Compounds and methods for peg metabolite and peg breakdown product assays
JP6983660B2 (ja) 2015-05-08 2021-12-17 スペクトラル プラットフォームス インコーポレイテッド アルブミンに基づく非共有結合性複合体およびその使用方法
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
WO2018175346A1 (en) 2017-03-20 2018-09-27 Spectral Platforms, Inc. Spectroscopic methods to detect and characterize microorganisms
US20220023399A1 (en) * 2017-07-10 2022-01-27 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
CN110183519B (zh) * 2019-05-06 2023-04-11 大邦(湖南)生物制药有限公司 一种达巴万星关键中间体a40926的分离纯化方法
CN112480214B (zh) * 2020-12-14 2023-03-28 成都雅途生物技术有限公司 一种达巴万星关键中间体a40926的制备方法
EP4014965A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CA3204571A1 (en) 2021-01-11 2022-07-14 Vidar Bjornstad Synthesis process
CN115215926A (zh) * 2022-08-12 2022-10-21 丽珠集团福州福兴医药有限公司 达巴万星母核及其纯化方法、达巴万星及其合成方法
AU2023359653A1 (en) * 2022-10-12 2025-05-29 Hikma Pharmaceuticals Usa Inc. Liquid dalbavancin composition
EP4601615A1 (en) 2022-10-12 2025-08-20 Hikma Pharmaceuticals USA Inc. Liquid dalbavancin composition
EP4431083A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
EP4431084A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
WO2025158262A1 (en) 2024-01-23 2025-07-31 Lupin Limited Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation
GB202405996D0 (en) * 2024-04-29 2024-06-12 Arecor Ltd Novel compositions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US541616A (en) * 1895-06-25 Elevator attachment
US573679A (en) * 1896-12-22 Apparatus for mowing hay
GB1496386A (en) * 1975-03-05 1977-12-30 Lepetit Spa Antibiotics
US4195079A (en) * 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
FI73697C (fi) * 1982-06-08 1987-11-09 Lepetit Spa Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2.
FR2548021B1 (fr) 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8415092D0 (en) * 1984-06-13 1984-07-18 Lepetit Spa Ester derivatives
GB8425685D0 (en) 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
GB8428619D0 (en) * 1984-11-13 1984-12-19 Lepetit Spa Derivatives of antibiotic l 17046
US4914187A (en) * 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
GB8512795D0 (en) 1985-05-21 1985-06-26 Lepetit Spa Increasing ratio of components of teicoplanin a2 complex
GB8531846D0 (en) * 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608809D0 (en) * 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
GB8621912D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GB8621911D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
GB8715735D0 (en) * 1987-07-03 1987-08-12 Lepetit Spa De-mannosyl teicoplanin derivatives
US4882313A (en) * 1987-07-31 1989-11-21 Smithkline Beckman Corporation Carboxamide derivatives of glycopeptides
GB8726859D0 (en) 1987-11-17 1987-12-23 Lepetit Spa 22-dechlorotei-coplanins
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2628269B1 (fr) * 1988-03-04 1990-07-27 Sgs Thomson Microelectronics Dispositif de demarrage progressif d'une alimentation a decoupage
ATE134646T1 (de) 1988-12-27 1996-03-15 Lepetit Spa C63-amidderivate von 34-de(acetylglucosaminyl)-34-deoxy-teicoplanine
IE64155B1 (en) 1989-03-29 1995-07-12 Lepetit Spa New substituted alkylamide derivatives of teicoplanin
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
US5030619A (en) * 1990-04-16 1991-07-09 Miles Inc. Synergistic fungicidal composition
US5606036A (en) * 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
KR100242682B1 (ko) 1991-07-29 2000-02-01 클라우디오 쿼르타 항생물질 a 40926의 아미드 유도체
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5882900A (en) * 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CA2112776C (en) * 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
ATE235549T1 (de) * 1993-04-30 2003-04-15 Biognostik Ges Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2
SI0801655T1 (en) * 1995-02-07 1998-08-31 Biosearch Italia S.P.A. Basic proline-amide derivatives of ge 2270 and ge 2270-like antibiotics
SI9500039B (sl) * 1995-02-07 2002-02-28 Lek, Nov kombiniran postopek čiščenja Vankomicin hidroklorida
JP3518606B2 (ja) * 1995-02-07 2004-04-12 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ Ｇｅ２２７０及びｇｅ２２７０−様抗生物質の塩基性オキサゾリン−アミド誘導体
US5789308A (en) * 1995-06-06 1998-08-04 Advanced Micro Devices, Inc. Manufacturing method for wafer slice starting material to optimize extrinsic gettering during semiconductor fabrication
CA2180206A1 (en) * 1995-06-30 1996-12-31 Motoya Ohshika Freeze-dried preparation for pharmaceutical use
DE69633234T2 (de) * 1995-07-05 2005-09-15 Aventis Bulk S.P.A. Reinigung von dalbeheptide-antibiotika mittels isoelektrofokussierung
DE19600590A1 (de) * 1996-01-10 1997-07-24 Tzn Forschung & Entwicklung Schutzvorrichtung für optische Systeme zur Vermeidung von Schäden bei Bestrahlung dieser Systeme mit Laserlicht
JP2000505438A (ja) * 1996-02-14 2000-05-09 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ 抗生物質ＧＥ２２７０因子Ｃ▲下２ａ▼、Ｄ▲下２▼およびＥの誘導体
AU2441697A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Covalently-linked glycopeptide dimers
KR20000010589A (ko) * 1996-04-23 2000-02-15 클라우디오 쿼르타 항생제a40926의아미드유도체의개선된화학적제조방법
US5935238A (en) * 1997-06-19 1999-08-10 Sun Microsystems, Inc. Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles
JP4204655B2 (ja) * 1997-08-08 2009-01-07 株式会社ルネサステクノロジ パルス出力機能付マイクロコンピュータ
CA2255140A1 (en) 1997-12-23 1999-06-23 Eli Lilly And Company Echinocandin binding domain of 1,3-.beta.-glucan synthase
US6541616B1 (en) * 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
US6417180B1 (en) 1998-10-07 2002-07-09 University Of Massachusetts Zinc finger-reactive antimicrobial compounds
DE69908819T2 (de) * 1998-12-23 2004-05-06 Theravance, Inc., South San Francisco Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
WO2003070756A2 (de) 2002-02-18 2003-08-28 Combinature Biopharm Ag Neue glycopeptid-antibiotika und verfahren zu deren synthetisierung
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
AU2003299561A1 (en) 2002-11-18 2004-06-15 Vicuron Pharmaceuticals Inc. Compositions and methods for treating bacterial infections with protein-dalbavancin complexes

Also Published As

Publication number Publication date
US6900175B2 (en) 2005-05-31
US7115564B2 (en) 2006-10-03
US20050130914A1 (en) 2005-06-16
NO20052362L (no) 2005-08-17
DK1565201T3 (en) 2019-02-25
ES2712656T3 (es) 2019-05-14
JP2011157381A (ja) 2011-08-18
CA2506236C (en) 2018-07-17
US20040198715A1 (en) 2004-10-07
EP1565201B1 (en) 2018-10-31
PT1565201T (pt) 2019-02-05
JP5519090B2 (ja) 2014-06-11
US20050032721A1 (en) 2005-02-10
US20090305953A1 (en) 2009-12-10
JP2006514092A (ja) 2006-04-27
MXPA05005338A (es) 2005-12-14
HUE041133T2 (hu) 2019-05-28
WO2004046196A2 (en) 2004-06-03
HK1083684A1 (en) 2006-07-07
HK1114014A1 (en) 2008-10-24
WO2004046196A3 (en) 2004-08-19
AU2003298662A1 (en) 2004-06-15
IL239913A0 (en) 2015-08-31
US20040224908A1 (en) 2004-11-11
US20050004011A1 (en) 2005-01-06
KR20050094396A (ko) 2005-09-27
WO2004045637A1 (en) 2004-06-03
US20090298748A1 (en) 2009-12-03
IL230875A0 (en) 2014-03-31
US20040220122A1 (en) 2004-11-04
AU2003294262A1 (en) 2004-06-15
CA2506236A1 (en) 2004-06-03
KR20120056310A (ko) 2012-06-01
IL168327A (en) 2014-02-27
US20050130909A1 (en) 2005-06-16
US20040142883A1 (en) 2004-07-22
NO20052362D0 (no) 2005-05-12
JP2013155188A (ja) 2013-08-15
EP1565201A1 (en) 2005-08-24
WO2004045636A1 (en) 2004-06-03
AU2003294262B2 (en) 2007-08-23
KR101173310B1 (ko) 2012-08-10
US20050090433A1 (en) 2005-04-28
IL239913B (en) 2019-01-31
US20040197415A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
AU2003299561A1 (en) Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
AU2003901008A0 (en) Composition for the treatment and prevention of bacterial infections
AU2001268564A1 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
AU2003290867A1 (en) Methods and products for treating staphylococcal infections
AU2003266058A1 (en) Antimicrobial composition and method for use
AU2003230750A1 (en) Compositions and methods for treating cancer
EP1594444A3 (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
MY138285A (en) Fab i inhibitors
AU2003284242A1 (en) Methods and compositions for use in treating cancer
HK1049656A1 (zh) Fab i抑制剂
ZA200507070B (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
AU2003225535A1 (en) Methods and compositions for treating cancer
AU2003242404A1 (en) Antibacterial agent and antibacterial composition
AU2002356868A1 (en) Methods for the prevention or treatment of bacterial and fungal infections
AU2003257109A1 (en) Compositions and methods for molecular biology
AU2003297573A1 (en) Compositions and methods for treating transplants
AU2003239132A1 (en) Methods and compositions for preventing and treating microbial infections
AU2003296963A1 (en) Methods and compositions for treating and preventing ear infections
AU2002353774A1 (en) Products and methods for treating microbial infections
AU2003259202A1 (en) Compositions and methods for treating and preventing infection
AU2003290506A1 (en) Methods and devices for treating severe peripheral bacterial infections
AU2003298708A1 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
AU2002334761A1 (en) Methods of treating drug-resistant bacterial infections
AU2003275069A1 (en) Compositions and methods for preventing infection
AU2003303948A1 (en) Compositions and methods for preventing infection

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase